This activity is supported by an independent educational grant from Amicus.
Join Barbara Burton, MD, Emeritus Professor, Northwestern University in discussion of how recognizing progression in late-onset Pompe disease can be challenging when individual measures remain within expected variability. This module explores how to identify meaningful changes over time by looking beyond single timepoints, tracking trajectories from best-on-treatment values, and responding to subtle changes in symptoms and function.
Session highlights
- Recognize early signals of progression by identifying subtle changes in motor function, respiratory symptoms, fatigue, and daily activities.
- Interpret trajectories over time by comparing serial measurements with the patient's own best-on-treatment values rather than relying on isolated results.
- Know when to trigger reassessment when consistent multi-domain changes, new nocturnal symptoms, or loss of functional reserve emerge.
- Use documentation to drive action by recording the trajectory, reassessment triggers, planned investigations, and review date.
This is Module One of Three, find Modules Two and Three here.
Who Should Participate
This program is designed for healthcare practitioners treating adults with Late-Onset Pompe Disease (LOPD), including:
- Primary Care Leads: Including neuromuscular specialists, neurologists, and metabolic disease specialists involved in direct monitoring, ongoing treatment, and disease management.
- Multidisciplinary Team Members: Including pulmonologists/respiratory physicians, geneticists, genetic counselors, rehabilitation specialists, advanced practice providers (NPs/PAs), and neuromuscular nurses involved in comprehensive LOPD care.
Prefer to read? See our key clinical summary here
Faculty
Barbara Burton, MD, Emeritus Professor, Northwestern University
Barbara K. Burton, MD, is a medical geneticist and faculty member at Northwestern University Feinberg School of Medicine. Triple-board-certified in pediatrics, clinical genetics, and clinical biochemical genetics. Dr. Burton’s clinical practice and research focus on the diagnosis, management, and treatment of inherited metabolic disorders and rare genetic conditions. She possesses specialized expertise in disorders identified through newborn screening—such as phenylketonuria (PKU)—as well as lysosomal storage disorders, and actively serves as an investigator in clinical trials evaluating novel therapies for rare diseases.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Prof. Em. Barbara Burton has the following relevant financial relationships: BioMarin: Speaker, consultant; Chiesi: Speaker; Denali: Speaker, consultant; JCR Pharma: Consultant; Moderna: Consultant.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until October 26th 2027. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This continuing education activity is active starting October 13th 2026, and will expire on October 26th 2027.
Estimated time to complete this activity: 15 Minutes